NBIX - Sosei to get $30M from Neurocrine as schizophrenia drug gets FDA nod to enter phase 2 trial

• Sosei Group ( OTCPK:SOLTF ) is getting $30M as a milestone payment from Neurocrine Biosciences ( NASDAQ: NBIX ) as NBI-1117568 was cleared by the U.S. Food and Drug Administration (FDA) for a phase 2 trial to treat schizophrenia.
• Neurocrine's investigational new drug (IND) application seeking to start the phase 2 study was accepted by the U.S. FDA, Sosei noted.
• NBI-1117568, which was discovered by Sosei, has been under development as per a 2021 collaboration with Neurocrine to treat major neurological disorders
• "We are excited to advance the lead asset in our strategic collaboration, NBI-1117568, into a Phase 2 study for the treatment of schizophrenia this year and look forward to our continued partnership with the Sosei Heptares team," said Neurocrine Chief Medical Officer Eiry Roberts.

For further details see: